基于“肠肝轴”探析代谢相关性脂肪性肝病中西医发病演变规律

doi:10.3969/j.issn.1672-5069.2026.02.002

Abstract

Zhao Zhao, Chen Xingyu, Ma Zhendong, et al. Chinese and western medical pathogenesis of metabolic-related fatty liver disease based on the“gut-liver axis”[J]. Journal of Practical Hepatology, 2026, 29(2): 166-169.

References

[1] Zeng J,Fan J G. From NAFLD to MAFLD:Not just a change in the name. Hepatobiliary Pancreat Dis Int,2022,21(6):511-513.
[2] Mantovani A,Scorletti E,Mosca A,et al. Complications,morbidity and mortality of nonalcoholic fatty liver disease. Metabolism,2020,111S:154170.
[3] Chan K E,Koh T J L,Tang A S P,et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease:A meta-analysis and systematic review of 10739607 individuals. J Clin Endocrinol Metab,107,9 (2022):2691-2700.
[4] Riazi K,Azhari H,Charette J H,et al. The prevalence and incidence of NAFLD worldwide:A systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2022,7(9):851-861.
[5] Fouad Y,Alboraie M,Shiha G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatol Int,2024,18(Suppl 2):827-833.
[6] 姚树坤,刘婧,周天惠.代谢相关脂肪性肝病的发病机制与中医病机.临床肝胆病杂志,2024,40(10):1954-1958.
[7] 董博一,杜琳.基于“浊毒”理论及肠道微生态紊乱探究针刺治疗非酒精性脂肪性肝炎.中西医结合肝病杂志,2025,35(4):472-476.
[8] 熊壮,孟香彤,沈东,等.刘铁军“脏毒腑秽学说”的构建与应用.长春中医药大学学报,2021,37(4):763-766.
[9] Tripathi A,Debelius J,Brenner,et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol,2018,15(7):397-411.
[10] 段旭冰,陈文慧,王仕奇,等.非酒精性脂肪性肝病伏邪“痰浊脂膏”与脂稳态关系探究.中华中医药杂志,2021,36(12):7099-7102.
[11] 隋晓丹,邓厚波,刘铁军.中医对非酒精性脂肪肝病机辩证研究进展.中国实用医药,2013,8(26):247-248.
[12] 万俊阳,王岩,张明香.基于“浊毒”理论探讨脂质代谢异常与代谢相关脂肪性肝病.中医临床研究,2022,14(10):97-100.
[13] 王梦依,汪卓,刘洋.肠道菌群调控脂质代谢作用与机制的研究进展.微生物学通报,2025,52(3):917-930.
[14] Ouyang S,Zhuo S,Yang M,et al. Glycerol kinase drives hepatic de novo lipogenesis and triglyceride synthesis in nonalcoholic fatty liver by activating SREBP-1c transcription,upregulating DGAT1/2 expression,and promoting glycerol metabolism. Adv Sci (Weinh),2024,11(46):e2401311.
[15] Brütting C,Lara Bisch M,Brandsch C,et al. Impact of dietary propionate on fructose-induced changes in lipid metabolism,gut microbiota and short-chain fatty acids in mice. Int J Food Sci Nutr,2021,72(2):160-173.
[16] Xu H,Fang F,Wu K,et al. Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia. Microbiome,2023,11(1):262.
[17] Clifford B L,Sedgeman L R,Williams K J,et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab,2021,33(8):1671-1684.
[18] Syed-Abdul M M. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites,2023,14(1):12.
[19] Pinanga Y D,Pyo K H,Shin E A,et al. Association between hepatocyte TM4SF5 expression and gut microbiome dysbiosis during non-alcoholic fatty liver disease development. Life Sci,2024,358:123164.
[20] Mou Y,Du Y,Zhou L,et al. Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation,neurodegeneration,and aging. Front Immunol,2022,13:796288.
[21] 李欣,吴伟华.肠道稳态与慢性低度系统性炎症.医学综述,2018,24(7):1354-1359.
[22] 孙智媛,陈凤鸣,钟颂石,等.肠-肝轴:肠道微生态与动物肝脏疾病.中国兽医学报,2022,42(1):175-182.
[23] Sehgal R,de Mello V D,Männistö V,et al. Indolepropionic acid,a gut bacteria-produced tryptophan metabolite and the risk of type 2 diabetes and non-alcoholic fatty liver disease. Nutrients,2022,14(21):4695.
[24] Chen C Y,Ho H C. Roles of gut microbes in metabolic-associated fatty liver disease. Tzu Chi Med J,2023,35(4):279-289.
[25] Olona A,Hateley C,Muralidharan S,et al. Sphingolipid metabolism during Toll-like receptor 4 (TLR4)-mediated macrophage activation. Br J Pharmacol,2021,178(23):4575-4587.
[26] Mou W L,Chen S R,Wu Z T,et al. LPS-TLR4/MD-2-TNF-α signaling mediates alcohol-induced liver fibrosis in rats. J Toxicol Pathol,2022,35(2):193-203.
[27] He S,Cui S,Song W,et al. Interleukin-17 weakens the NAFLD/NASH process by facilitating intestinal barrier restoration depending on the gut microbiota. mBio,2022,13(2):e0368821.
[28] Zhang W,Liu K,Ren G M,et al. BRISC is required for optimal activation of NF-κB in Kupffer cells induced by LPS and contributes to acute liver injury. Cell Death Dis,2023,14(11):743.
[29] 李姗,周志文,刘湘花,等.黄杞苷干预NF-κB信号通路抑制巨噬细胞炎症反应及氧化应激.中国感染控制杂志,2023,22(4):383-390.
[30] 徐佳浩,梁计陵,李佳航,等.运动改善小鼠非酒精性脂肪肝纤维化的生物信息学分析.中国康复医学杂志,2025,40(7):986-994.
[31] Zhang M,Serna-Salas S,Damba T,et al. Hepatic stellate cell senescence in liver fibrosis:Characteristics,mechanisms and perspectives. Mech Ageing Dev,2021,199:111572.
[32] 郑博文,王佳慧,罗淑娟,等.肠道菌群丰度和多样性对肝纤维化的加速或延缓作用及特殊菌群的防治研究进展.中国药理学与毒理学杂志,2022,36(3):217-224.
[33] Su X,Gao Y,Yang R. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity. Front Immunol,2023,14:1127743.
[34] Yang D,Wei X,Zhang B,et al. Probiotics protect against hepatic steatosis in tris (2-chloroethyl) phosphate-induced metabolic disorder of mice via FXR signaling. Food Chem Toxicol,2022,169:113440.
[35] Sørensen M D,Thiele M,Krag A,et al. Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. Pathol Res Pract,2022,231:153798.
[36] Li D,Feng Y,Tian M,et al. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation. Microbiome,2021,9(1):83.
[37] Qiu Y Y,Zhang J,Zeng F Y,et al. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res,2023,192:106786.
[38] Pastore M,Caligiuri A,Raggi C,et al. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Rep,2022,4(4):100444.
[39] Riva A,Gray E H,Azarian S,et al. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Rep,2020,2(6):100151.
[40] Akkız H,Gieseler R K,Canbay A. Liver fibrosis:From basic science towards clinical progress,focusing on the central role of hepatic stellate cells. Int J Mol Sci,2024,25(14):7873.

Chinese and western medical pathogenesis of metabolic-related fatty liver disease based on the“gut-liver axis”

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Jin, Li Jiahao, Xu Yuxuan, et al. Role of lipopolysaccharide in the pathogenesis of metabolic dysfunction-associated steatotic liver disease [J]. Journal of Practical Hepatology, 2026, 29(2): 161-166.
[2]	Yao Yu, Ning Bo. Pathogenesis,spontaneous recanalization and anticoagulation therapy in patients with liver cirrhosis and portal vein thrombosis [J]. Journal of Practical Hepatology, 2025, 28(6): 801-804.
[3]	Hou Yilin, Cao Fenghua, Ji Xiaoyan, et al. Changes of intestinal flora as well as serum interliukin-17 and interferon-γ levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 819-822.
[4]	Chen Huiting, Zhou Yongjian. Role of gut-liver axis in patients with chronic cholestatic liver diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 305-307.
[5]	Wang Lingyun, Zhou Yongjian. Gut microbiota in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 317-319.
[6]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[7]	Huang Danxia, Zhao Zhihui, Xiao Yuexing, et al. Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats [J]. Journal of Practical Hepatology, 2023, 26(1): 23-26.
[8]	Luo Nan, Li Rongkuan. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 616-619.
[9]	Zhang Gaixia, Chen Haizhen, Huang Jing. Intestinal microecology in patients with alcoholic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 757-760.
[10]	Wang Fang, Gao Xiaoxia, Wang Qingqiang. Short-term efficacy of Huanglian Jiedu decoction and probiotics supplement in intervention of patients with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2022, 25(2): 235-238.
[11]	Lin Ning, Kong Ming, Duan Zhongping. Pathogenesis of sarcopenia in liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 301-304.
[12]	Ren Jie, Hao Qiaoyun, Huang Chenghe, et al. Structure of intestinal flora changes in patients with non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(1): 54-57.
[13]	Zhu Nannan, Jiang Xiaohong, Zhou Jiayan, et al. Serum uric acid levels and its clinical implications in patients with diabetes mellitus type 2 and concomitant metabolism-related fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(6): 839-842.
[14]	Ji Minyou, Li Chao, Zhao Xingzhong, et al. Intestinal flora changes in patients with hepatitis B-induced liver cirrhosis after entecavir and glycyrrhizin combination treatment [J]. Journal of Practical Hepatology, 2021, 24(5): 641-644.
[15]	Yu Lei, Sun Chao, Zhang Manxu. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 476-479.